<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054062</url>
  </required_header>
  <id_info>
    <org_study_id>METCZ20210103</org_study_id>
    <nct_id>NCT05054062</nct_id>
  </id_info>
  <brief_title>Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients</brief_title>
  <acronym>TRACIE</acronym>
  <official_title>Exploring an Alternative Pre-operative Sentinel Lymph Node Mapping Method Using a Magnetic Tracer and MRI for Potential Use in Melanoma Patients: Imaging Protocol in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zuyderland Medisch Centrum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zuyderland Medisch Centrum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sentinel lymph node biopsy (SLNB) is crucial in the management of malignant melanoma&#xD;
      treatment and is currently performed by pre-operatively inject a colloid nanomaterial labeled&#xD;
      with Technetium (99mTc) as radioactive tracer. Intra-operatively, Patent Blue (PB) will be&#xD;
      injected to improve the visualization of the lymphatic tract. However, current pre-operative&#xD;
      SLN mapping technique, is associated with disadvantages as radiation exposure for both&#xD;
      patients and health care personnel and logistic challenges, because of time constraints due&#xD;
      to short half-live time of 99mTc.&#xD;
&#xD;
      Superparamagnetic iron oxide (SPIO) is novel, non-radioactive technique using a magnetic&#xD;
      tracer (Magtrace® (Endomagnetics Ltd.)) and several studies showed that SPIO is non-inferior&#xD;
      to dual tracing with 99mTc and PB in breast cancer patients. SPIO is expected to be&#xD;
      non-inferior to dual tracing with 99mTc and PB in melanoma patients. However, further&#xD;
      research is needed to demonstrate the use of SPIO in pre-operative Magnetic Resonance Imaging&#xD;
      (MRI) scanning. Guidance on pre-operative MRI use is rather limited, though fundamental in&#xD;
      the intended research process.&#xD;
&#xD;
      Hence, the aim of this subprotocol study, which includes healthy subjects, is to develop a&#xD;
      pre-operative MRI protocol for melanoma patients. The acquired knowledge will be used to&#xD;
      design a feasibility study, including a larger group of melanoma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Actual">September 13, 2021</completion_date>
  <primary_completion_date type="Actual">September 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPIO dosage in milliliters</measure>
    <time_frame>Three weeks</time_frame>
    <description>SPIO dosage in milliliters will be assessed to develop a pre-operative MRI protocol. Testing will be perform in healthy subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Massage duration in seconds</measure>
    <time_frame>Three weeks</time_frame>
    <description>Massage duration in seconds will be assessed to develop a pre-operative MRI protocol. Testing will be perform in healthy subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to artefact appearance in minutes</measure>
    <time_frame>Three weeks</time_frame>
    <description>Time to artefact appearance in minutes will be assessed to develop a pre-operative MRI protocol. Testing will be perform in healthy subjects.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Healthy participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sentinel node mapping using MRI</intervention_name>
    <description>Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI</description>
    <arm_group_label>Healthy participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy participants;&#xD;
&#xD;
          -  Participants should be ≥18 years of age at the time of consent;&#xD;
&#xD;
          -  Participants should be willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known intolerance/hypersensitivity to iron, dextran compounds or Magtrace® itself;&#xD;
&#xD;
          -  Standard MRI exclusion criteria:&#xD;
&#xD;
          -  Implantable (electrical) devices (e.g. pacemaker, cochlear implants, neurostimulator);&#xD;
&#xD;
          -  Any other metal implants;&#xD;
&#xD;
          -  Claustrophobia;&#xD;
&#xD;
          -  MR-incompatible prosthetic heart valves;&#xD;
&#xD;
          -  Tattoos inked with metallic dye.&#xD;
&#xD;
          -  Participants who refuse to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zuyderland Medical Center</name>
      <address>
        <city>Sittard</city>
        <state>Limburg</state>
        <zip>6162BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zuyderland Medisch Centrum</investigator_affiliation>
    <investigator_full_name>James van Bastelaar</investigator_full_name>
    <investigator_title>Head of department of Surgery (Surgical Oncologist)</investigator_title>
  </responsible_party>
  <keyword>Magnetic tracer</keyword>
  <keyword>Sentinel lymph node</keyword>
  <keyword>Melanoma</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

